These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 19923168)

  • 81. Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study.
    Cowper PA; Pan W; Anstrom KJ; Kaul P; Wallentin L; Davidson-Ray L; Nikolic E; Janzon M; Levin LÅ; Cannon CP; Harrington RA; Mark DB
    J Am Coll Cardiol; 2015 Feb; 65(5):465-76. PubMed ID: 25660925
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.
    Anderson SD; Shah NK; Yim J; Epstein BJ
    Ann Pharmacother; 2010 Mar; 44(3):524-37. PubMed ID: 20124464
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
    Lewis BS; Mehta SR; Fox KA; Halon DA; Zhao F; Peters RJ; Keltai M; Budaj A; Yusuf S;
    Am Heart J; 2005 Dec; 150(6):1177-84. PubMed ID: 16338255
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Clopidogrel in coronary artery disease: update 2012.
    Huber K
    Adv Cardiol; 2012; 47():31-8. PubMed ID: 22906901
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
    Torngren K; Ohman J; Salmi H; Larsson J; Erlinge D
    Cardiology; 2013; 124(4):252-8. PubMed ID: 23594617
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G
    Expert Opin Pharmacother; 2015; 16(12):1739-47. PubMed ID: 26067422
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
    White HD
    Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
    Husted S
    Postgrad Med; 2011 Nov; 123(6):79-90. PubMed ID: 22104457
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
    Price MJ; Walder JS; Baker BA; Heiselman DE; Jakubowski JA; Logan DK; Winters KJ; Li W; Angiolillo DJ
    J Am Coll Cardiol; 2012 Jun; 59(25):2338-43. PubMed ID: 22698488
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial.
    Suh JW; Seung KB; Gwak CH; Kim KS; Hong SJ; Park TH; Kim SH; Choi YJ; Joo SJ; Tahk SJ; Kim HS
    Clin Ther; 2011 Aug; 33(8):1057-68. PubMed ID: 21816478
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.
    Butler K; Teng R
    Br J Clin Pharmacol; 2010 Jul; 70(1):65-77. PubMed ID: 20642549
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Randomized Trial Comparing the Effects of Ticagrelor Versus Clopidogrel on Myocardial Perfusion in Patients With Coronary Artery Disease.
    Pelletier-Galarneau M; Hunter CRRN; Ascah KJ; Beanlands RSB; Dwivedi G; deKemp RA; Chow BJW; Ruddy TD
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28465300
    [TBL] [Abstract][Full Text] [Related]  

  • 93. ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy.
    Armstrong PW; Siha H; Fu Y; Westerhout CM; Steg PG; James SK; Storey RF; Horrow J; Katus H; Clemmensen P; Harrington RA; Wallentin L
    Circulation; 2012 Jan; 125(3):514-21. PubMed ID: 22179530
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
    Parodi G; Bellandi B; Valenti R; Migliorini A; Marcucci R; Carrabba N; Giurlani L; Gensini GF; Abbate R; Antoniucci D
    Am Heart J; 2014 Jun; 167(6):909-14. PubMed ID: 24890542
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Ticagrelor for the treatment of arterial thrombosis.
    Gurbel PA; Kereiakes DJ; Tantry US
    Expert Opin Pharmacother; 2010 Sep; 11(13):2251-9. PubMed ID: 20707759
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Steg PG; James S; Harrington RA; Ardissino D; Becker RC; Cannon CP; Emanuelsson H; Finkelstein A; Husted S; Katus H; Kilhamn J; Olofsson S; Storey RF; Weaver WD; Wallentin L;
    Circulation; 2010 Nov; 122(21):2131-41. PubMed ID: 21060072
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2).
    Angiolillo DJ; Curzen N; Gurbel P; Vaitkus P; Lipkin F; Li W; Jakubowski JA; Zettler M; Effron MB; Trenk D
    J Am Coll Cardiol; 2014 Apr; 63(15):1500-9. PubMed ID: 24333493
    [TBL] [Abstract][Full Text] [Related]  

  • 98. One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease: A randomized, single-blind, crossover clinical study.
    He M; Liu B; Sun D; Pan Y; Zheng W; Shi J; Zhao S; Dong X; Lu S; Li M; Han Y; Li Y
    Int J Cardiol; 2016 Jul; 215():209-13. PubMed ID: 27128532
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Comparison of effect of locally available brands of clopidogrel on platelet aggregation in patients with coronary artery disease.
    Khan SB; Hameedullah ; Noor L; Hafeezullah M; Awan ZA; ud Din S
    J Ayub Med Coll Abbottabad; 2010; 22(1):115-7. PubMed ID: 21409920
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
    Mahaffey KW; Wojdyla DM; Carroll K; Becker RC; Storey RF; Angiolillo DJ; Held C; Cannon CP; James S; Pieper KS; Horrow J; Harrington RA; Wallentin L;
    Circulation; 2011 Aug; 124(5):544-54. PubMed ID: 21709065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.